Therapy Area
Allergy & Immunology
Cardiology
Dermatology
Diabetes
Flagship Journal
Gastroenterology
General Healthcare
Hematology
Hepatology
Innovations
Interventional Cardiology
Microbiology & Infectious Diseases
Nephrology
Neurology
Oncology
Radiology
Reproductive Health
Respiratory
Rheumatology
Urology
Podcasts
Journals
Webinars
Collaborate
Media Pack
Editorial Enquiries
Contributors & Authors
Submit a Paper
Media Partners
Pharma Partners
About
About
EQOH
Careers
Contact Us
EMJ Gold
search
Subscribe
FREE
Subscribe to EMJ GOLD
Subscribe to EMJ
You must accept all conditions before being able to view the post
Continue
EUR
USA
EUR
USA
Therapy Area
Allergy & Immunology
Cardiology
Dermatology
Diabetes
Flagship Journal
Gastroenterology
General Healthcare
Hematology
Hepatology
Innovations
Interventional Cardiology
Microbiology & Infectious Diseases
Nephrology
Neurology
Oncology
Radiology
Reproductive Health
Respiratory
Rheumatology
Urology
Podcasts
Journals
Webinars
Collaborate
Media Pack
Editorial Enquiries
Contributors & Authors
Submit a Paper
Media Partners
Pharma Partners
About
About
EQOH
Careers
Contact Us
EMJ Gold
Subscribe
FREE
Subscribe to EMJ GOLD
Subscribe to EMJ
Hematology
Filter
Journals
About
Congress reviews
Abstracts
Articles
Podcasts
Videos & Webinars
News
Infographics
Submit A Paper
Impact of Normalisation of Haemostasis for People with Haemophilia A
July 2024
Read more
26th June 2015
Results of the phase 3 PERSIST-1 trial of pacritinib in myelofibrosis
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Ruben A. Mesa, MD, Chair of Hematology at Mayo Clinic, Arizona, TX, discusses…
26th June 2015
The crucial roles of GFI1B in platelet development
The identification of eight new Growth Factor Independence 1B (GFI1B) variants in families with bleeding and platelet disorders may result in the…
26th June 2015
Pacritinib therapy led to symptom improvement in myelofibrosis
The phase 3 PERSIST-1 study showed that pacritinib, a selective inhibitor of Janus Kinase 2 (JAK2) and Fms-Like Tyrosine Kinase-3 (FLT3), is more…
26th June 2015
Treatment and outcome of CML patients from the EUTOS population-based registry
The European Treatment Outcome Study (EUTOS) investigated the treatment and treatment outcome of patients with chronic myeloid leukaemia (CML).
26th June 2015
Venetoclax (ABT-199/GDC-0199) plus rituximab shows promise in relapsed/refractory CLL
n a phase 1b, open-label, dose-escalation, multicentre study of patients with relapsed or refractory chronic lymphocytic leukaemia (CLL), the combination…
26th June 2015
Adding elotuzumab to standard treatment for myeloma reduced disease progression
ELOQUENT-2, a phase 3, randomised, open-label study of lenalidomide and dexamethasone with or without elotuzumab in patients with relapsed or refractory…
12th May 2015
Dr Keith Stewart chairs a discussion on tumour biology-guided treatment for multiple myeloma
At the Myeloma 2015 meeting, Dr Keith Stewart (Mayo Clinic, Scottsdale, AZ) chairs a discussion with Prof Gareth Morgan (University of Arkansas…
12th May 2015
Clinical significance of progenitor cells in multiple myeloma
Prof Kenneth Anderson (Harvard Medical School, Boston, MA) chairs a discussion with Prof Leif Bergsagel (Mayo Clinic, Scottsdale, AZ) and Prof Gareth…
Loading posts...
« Previous
1
…
5
6
7
8
Next »